Your shopping cart is currently empty

Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent CXCR4 antagonist with anti-angiogenic properties, potentially valuable in treating choroid neovascularization.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | Inquiry | 6-8 weeks | 6-8 weeks | |
| 50 mg | Inquiry | 6-8 weeks | 6-8 weeks | |
| 100 mg | Inquiry | 6-8 weeks | 6-8 weeks |
| Description | Burixafor hydrobromide (TG-0054 hydrobromide) is an orally bioavailable and potent CXCR4 antagonist with anti-angiogenic properties, potentially valuable in treating choroid neovascularization. |
| In vitro | Burixafor hydrobromide mobilizes mesenchymal stem cells, attenuates inflammation, and preserves cardiac systolic function in a porcine model of myocardial infarction [2]. |
| Synonyms | TG-0054 hydrobromide |
| Molecular Weight | 647.644 |
| Formula | C27H52BrN8O3P |
| Cas No. | 1191450-19-7 |
| Smiles | Br.Nc1cc(nc(NCC2CCC(CNCCCNC3CCCCC3)CC2)n1)N1CCN(CCP(O)(O)=O)CC1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | H2O: 50 mg/mL (77.2 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
H2O
| |||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.